1171 related articles for article (PubMed ID: 6679957)
1. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
Pak CY; Sakhaee K; Fuller CJ
Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate.
Pak CY; Peterson R
Arch Intern Med; 1986 May; 146(5):863-7. PubMed ID: 3963975
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of calcium nephrolithiasis with potassium citrate.
Pak CY; Fuller C; Sakhaee K; Preminger GM; Britton F
J Urol; 1985 Jul; 134(1):11-9. PubMed ID: 3892044
[TBL] [Abstract][Full Text] [Related]
4. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
[TBL] [Abstract][Full Text] [Related]
5. Alkaline citrate in prevention of recurrent calcium oxalate stones.
Berg C
Scand J Urol Nephrol Suppl; 1990; 130():1-83. PubMed ID: 2291093
[TBL] [Abstract][Full Text] [Related]
6. Metabolic abnormalities associated with calyceal diverticular stones.
Auge BK; Maloney ME; Mathias BJ; Pietrow PK; Preminger GM
BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
[TBL] [Abstract][Full Text] [Related]
7. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
Jaipakdee S; Prasongwatana V; Premgamone A; Reungjui S; Tosukhowong P; Tungsanga K; Suwantrai S; Noppawinyoowong C; Maskasame S; Sriboonlue P
J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
[TBL] [Abstract][Full Text] [Related]
8. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
Sakhaee K; Poindexter JR; Griffith CS; Pak CY
J Urol; 2004 Sep; 172(3):958-61. PubMed ID: 15311008
[TBL] [Abstract][Full Text] [Related]
9. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions.
Pak CY; Heller HJ; Pearle MS; Odvina CV; Poindexter JR; Peterson RD
J Urol; 2003 Feb; 169(2):465-9. PubMed ID: 12544288
[TBL] [Abstract][Full Text] [Related]
10. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones.
Alvarez Arroyo MV; Traba ML; Rapado A
Urol Int; 1992; 48(3):342-6. PubMed ID: 1589930
[TBL] [Abstract][Full Text] [Related]
11. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
[TBL] [Abstract][Full Text] [Related]
12. Citrate and renal calculi.
Pak CY
Miner Electrolyte Metab; 1987; 13(4):257-66. PubMed ID: 3306318
[TBL] [Abstract][Full Text] [Related]
13. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate.
Pak CY; Fuller C
Ann Intern Med; 1986 Jan; 104(1):33-7. PubMed ID: 3940503
[TBL] [Abstract][Full Text] [Related]
15. Effects of citrate on the different phases of calcium oxalate crystallization.
Tiselius HG; Berg C; Fornander AM; Nilsson MA
Scanning Microsc; 1993 Mar; 7(1):381-9; discussion 389-90. PubMed ID: 8316807
[TBL] [Abstract][Full Text] [Related]
16. [Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria].
Hassani MA; Hennequin C; Lacour B; Daudon M
Prog Urol; 2005 Sep; 15(4):650-5. PubMed ID: 16459680
[TBL] [Abstract][Full Text] [Related]
17. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
Conte A; Pizá P; García-Raja A
Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
[TBL] [Abstract][Full Text] [Related]
18. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers.
Favus MJ; Coe FL
Scand J Urol Nephrol Suppl; 1980; 53():265-71. PubMed ID: 6938003
[TBL] [Abstract][Full Text] [Related]
19. Prevention of recurrent nephrolithiasis.
Goldfarb DS; Coe FL
Am Fam Physician; 1999 Nov; 60(8):2269-76. PubMed ID: 10593318
[TBL] [Abstract][Full Text] [Related]
20. Urine citrate and renal stone disease.
Goldberg H; Grass L; Vogl R; Rapoport A; Oreopoulos DG
CMAJ; 1989 Aug; 141(3):217-21. PubMed ID: 2665909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
